Catalent Pharma Solutions' latest expansion in Madison is bringing a boost to Wisconsin’s growing biohealth sector, with a ...

Catalent plans to invest an estimated $45 million to expand its facilities and purchase new equipment for its production ...

After a 54% rise year-to-date, at the current levels, Catalent stock (NYSE: CTLT), a global solutions provider for drugs, biologics, gene therapies, and consumer healthcare products, has little ...

Catalent Inc expects to cut by more than $400 million both its full-year revenue and core profit forecasts, the contract drug manufacturer said on Monday, sending its shares tumbling 27% to a ...

Catalent experienced operational issues and higher-than-expected costs at three of its manufacturing facilities, and management was overly optimistic about its previously stated fiscal-year 2023 ...

S ixteen billion dollars is a lot of money. But Monday’s announcement that the parent company of Novo Nordisk, the maker of the weight loss drug Wegovy, plans to buy Catalent, a company to which ...

Catalent also recently completed its acquisition of Metrics Contract Services, a full-service CDMO in Greenville for $475 million. The 333,000-square-foot site has 16 manufacturing suites and two ...

Catalent's shares shot up 12% on Monday as the contract drug manufacturer posted third-quarter revenue ahead of estimates after a long delay caused by persistent production issues at its major ...

Catalent continues to manufacture Wegovy after all, which promises to be a highly lucrative contract going forward, given analysts believe it may drive revenues in excess of $25bn per annum.

ROME (Reuters) -Italian authorities on Monday appointed a special commissioner to help Danish drugmaker Novo Nordisk speedily ...